Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
NCT02091375
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Dravet Syndrome
Interventions
DRUG:
GWP42003-P 20 mg/kg/day Dose
DRUG:
Placebo control
Sponsor
Jazz Pharmaceuticals